13 April 2026 – JPMC proudly announced the official launch of Nucleic Acid Amplification Testing (NAAT) today at Jerudong Park Medical Centre. The launch marks a significant milestone in strengthening laboratory diagnostic capabilities and enhancing blood safety standards in Brunei Darussalam.

The momentous occasion was graced by the Guest of Honour Yang Mulia Dk Hajah Dewi Sarwani Binti Pg Haji Sarpuddin, Board Member of JPMC. The ceremony commenced withthe recitation of Surah Al-Fatihah and Doa Selamat and a showcase of the new NAAT system.

Nucleic Acid Amplification Testing (NAAT), as utilised by the cobas® 5800 system, is an advanced testing method that detects viral genetic material (RNA/DNA) directly in donor blood samples. In addition to conventional antibody and antigen-based screening, NAAT can identify infections at a much earlier stage, before the body produces detectable antibodies or antigens.

By enabling earlier detection, this technology enhances the safety of blood transfusions and reduces the risk of infections going undetected. It also improves the sensitivity screening, supporting more reliable identification of viruses such as HIV and hepatitis, and ensuring safer outcomes for patients.

“This is about safer blood for every patient. NAAT allows us to detect infectious earlier and reduce risks across the board” said Yang Mulia Dr Awg Hj Mohamad Hj Kassim, Consultant Laboratory Manager at JPMC.

The introduction of NAAT enhances JPMC’s diagnostic capabilities by enabling more accurate and timely detection, while complementing existing screening methods and aligning with international best practices. This advancement supports safer blood transfusion processes and reinforces JPMC’s commitment to delivering high-quality, patient-centred care.

The event was attended by Senior Management Team of JPMC, healthcare professionals and key stakeholders, reflecting a shared commitment to advancing diagnostic excellence and patient safety.